View:
Download DOC
Download PDF
Download XLS
Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 23, 2008

 

 

HARVARD BIOSCIENCE, INC.

(Exact name of registrant as specified in charter)

 

 

 

Delaware   000-31923   04-3306140

(State or Other Jurisdiction

of Incorporation)

   (Commission File Number)  

(IRS Employer

Identification No.)

84 October Hill Road, Holliston, MA 01746

(Address of Principal Executive Offices) (Zip Code)

(508) 893-8999

(Registrant’s telephone number, including area code)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

On April 23, 2008, Mr. Bryce Chicoyne resigned as Chief Financial Officer of Harvard Bioscience, Inc. (the “Company”) effective May 9, 2008. Susan Luscinski, the Company’s Chief Operating Officer, will assume the role of interim principal accounting and financial officer effective May 9, 2008.

Susan Luscinski, age 51, has served as our Chief Operating Officer since August 2004. Ms. Luscinski served as our Chief Financial Officer from August 2001 until August 2004 and Vice President of Finance and Administration from May 1999 until August 2001. Ms. Luscinski served as our Corporate Controller from May 1988 until May 1999 and has served in various other positions at our company and its predecessor since January 1985.

On April 25, 2008, the Company issued a press release regarding the resignation of Mr. Chicoyne. The full text of the press release is attached as Exhibit 99.1 hereto and incorporated by reference herein.

 

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit

Number

  

Title

99.1   Press release of Harvard Bioscience, Inc. issued on April 25, 2008.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  HARVARD BIOSCIENCE, INC.
Date: April 25, 2008   By:  

/s/ Bryce Chicoyne

    Bryce Chicoyne
    Chief Financial Officer
Press release of Harvard Bioscience, Inc. issued on April 25, 2008.

EXHIBIT 99.1

LOGO

FOR IMMEDIATE RELEASE

CONTACTS:

 

David Green      Chane Graziano
President      CEO
dgreen@harvardbioscience.com      cgraziano@harvardbioscience.com
Tel: 508 893 8999     
Fax: 508 429 8478     

Harvard Bioscience Announces Resignation of Chief Financial Officer

Holliston, MA, April 25, 2008//— Harvard Bioscience, Inc. (Nasdaq: HBIO), announced that on April 23, 2008, Bryce Chicoyne resigned as its Chief Financial Officer. Mr. Chicoyne’s resignation is effective May 9, 2008. Mr. Chicoyne will continue to work with us, assisting us with transitional matters and the completion of our quarterly reporting process for the first quarter. Mr. Chicoyne has accepted the position of CFO at another company and his resignation did not relate to any disagreements with us on any matter related to our operations, policies or practices.

Beginning on May 9, 2008, Susan Luscinski, in addition to her responsibilities as Chief Operating Officer, will serve as our principal financial officer on an interim basis to succeed Mr. Chicoyne. Prior to her current role as COO, Ms. Luscinski served as our Chief Financial Officer from August 2001 until August 2004 and Vice President of Finance and Administration from May 1999 until August 2001. Ms. Luscinski served in various other positions at our company and its predecessor since January 1985.

“We would like to thank Bryce for all of his services during his tenure with the Company, including his important role in assisting in our implementation procedures to comply with Section 404 of the Sarbanes-Oxley Act. We believe he has created a strong finance team and reporting infrastructure, and we wish him well in his future endeavors. We are also fortunate to be able to reach out to Sue Luscinski, who has previously served as our CFO, to assist us with this critical role while we actively search for a new CFO,” said Chane Graziano, Chief Executive Officer of Harvard Bioscience.

About Harvard Bioscience

Harvard Bioscience (“HBIO”) is a global developer, manufacturer, and marketer of a broad range of specialized products, primarily scientific instruments and apparatus, used to advance life science research at pharmaceutical and biotechnology companies, universities and government laboratories worldwide. HBIO sells its products to thousands of researchers in over 100 countries primarily through its 900 page catalog (and various other specialty catalogs), its website and through its distributors, including GE Healthcare, Thermo Fisher Scientific and VWR. HBIO has sales and manufacturing operations in the United States, the United Kingdom, Germany, Spain and Austria with additional facilities in France and Canada. For more information, please visit www.harvardbioscience.com.

For investor inquiries, please call (508) 893-8066. Press releases may be found on our web site, http://www.harvardbioscience.com.